dc.contributor.author |
Lee, Tet Woo |
|
dc.contributor.author |
Lai, Amy |
|
dc.contributor.author |
Harms, Julia K |
|
dc.contributor.author |
Singleton, Dean C |
|
dc.contributor.author |
Dickson, Benjamin D |
|
dc.contributor.author |
Macann, Andrew MJ |
|
dc.contributor.author |
Hay, Michael P |
|
dc.contributor.author |
Jamieson, Stephen MF |
|
dc.coverage.spatial |
Switzerland |
|
dc.date.accessioned |
2023-01-24T02:53:32Z |
|
dc.date.available |
2023-01-24T02:53:32Z |
|
dc.date.issued |
2020-12 |
|
dc.identifier.citation |
(2020). Cancers, 12(12), E3743-. |
|
dc.identifier.issn |
2072-6694 |
|
dc.identifier.uri |
https://hdl.handle.net/2292/62544 |
|
dc.description.abstract |
Patient survival from head and neck squamous cell carcinoma (HNSCC), the seventh most common cause of cancer, has not markedly improved in recent years despite the approval of targeted therapies and immunotherapy agents. Precision medicine approaches that seek to individualise therapy through the use of predictive biomarkers and stratification strategies offer opportunities to improve therapeutic success in HNSCC. To enable precision medicine of HNSCC, an understanding of the microenvironment that influences tumour growth and response to therapy is required alongside research tools that recapitulate the features of human tumours. In this review, we highlight the importance of the tumour microenvironment in HNSCC, with a focus on tumour hypoxia, and discuss the fidelity of patient-derived xenograft and organoids for modelling human HNSCC and response to therapy. We describe the benefits of patient-derived models over alternative preclinical models and their limitations in clinical relevance and how these impact their utility in precision medicine in HNSCC for the discovery of new therapeutic agents, as well as predictive biomarkers to identify patients' most likely to respond to therapy. |
|
dc.format.medium |
Electronic |
|
dc.language |
eng |
|
dc.publisher |
MDPI |
|
dc.relation.ispartofseries |
Cancers |
|
dc.rights |
Items in ResearchSpace are protected by copyright, with all rights reserved, unless otherwise indicated. Previously published items are made available in accordance with the copyright policy of the publisher. |
|
dc.rights.uri |
https://researchspace.auckland.ac.nz/docs/uoa-docs/rights.htm |
|
dc.rights.uri |
https://creativecommons.org/licenses/by/4.0/ |
|
dc.subject |
head and neck squamous cell carcinoma |
|
dc.subject |
hypoxia |
|
dc.subject |
organoids |
|
dc.subject |
patient derived xenografts |
|
dc.subject |
precision medicine |
|
dc.subject |
tumour microenvironment |
|
dc.subject |
Biotechnology |
|
dc.subject |
Cancer |
|
dc.subject |
Orphan Drug |
|
dc.subject |
Rare Diseases |
|
dc.subject |
Dental/Oral and Craniofacial Disease |
|
dc.subject |
5.1 Pharmaceuticals |
|
dc.subject |
4.1 Discovery and preclinical testing of markers and technologies |
|
dc.subject |
5 Development of treatments and therapeutic interventions |
|
dc.subject |
4 Detection, screening and diagnosis |
|
dc.subject |
3 Good Health and Well Being |
|
dc.subject |
Science & Technology |
|
dc.subject |
Life Sciences & Biomedicine |
|
dc.subject |
Oncology |
|
dc.subject |
SQUAMOUS-CELL CARCINOMA |
|
dc.subject |
POSITRON-EMISSION-TOMOGRAPHY |
|
dc.subject |
HUMAN-PAPILLOMAVIRUS |
|
dc.subject |
GENE-EXPRESSION |
|
dc.subject |
IN-VITRO |
|
dc.subject |
HYPOXIC MODIFICATION |
|
dc.subject |
RADIATION-RESPONSE |
|
dc.subject |
PLUS CETUXIMAB |
|
dc.subject |
MESSENGER-RNA |
|
dc.subject |
STEM-CELLS |
|
dc.subject |
1112 Oncology and Carcinogenesis |
|
dc.title |
Patient-Derived Xenograft and Organoid Models for Precision Medicine Targeting of the Tumour Microenvironment in Head and Neck Cancer. |
|
dc.type |
Journal Article |
|
dc.identifier.doi |
10.3390/cancers12123743 |
|
pubs.issue |
12 |
|
pubs.begin-page |
E3743 |
|
pubs.volume |
12 |
|
dc.date.updated |
2022-12-14T23:00:17Z |
|
dc.rights.holder |
Copyright: The authors |
en |
dc.identifier.pmid |
33322840 (pubmed) |
|
pubs.author-url |
https://www.ncbi.nlm.nih.gov/pubmed/33322840 |
|
pubs.publication-status |
Published |
|
dc.rights.accessrights |
http://purl.org/eprint/accessRights/OpenAccess |
en |
pubs.subtype |
review-article |
|
pubs.subtype |
Review |
|
pubs.subtype |
Journal Article |
|
pubs.elements-id |
832573 |
|
pubs.org-id |
Medical and Health Sciences |
|
pubs.org-id |
Science |
|
pubs.org-id |
Science Research |
|
pubs.org-id |
Medical Sciences |
|
pubs.org-id |
Auckland Cancer Research |
|
pubs.org-id |
Molecular Medicine |
|
pubs.org-id |
Pharmacology |
|
pubs.org-id |
Maurice Wilkins Centre (2010-2014) |
|
dc.identifier.eissn |
2072-6694 |
|
dc.identifier.pii |
cancers12123743 |
|
pubs.number |
ARTN 3743 |
|
pubs.record-created-at-source-date |
2022-12-15 |
|
pubs.online-publication-date |
2020-12-12 |
|